Just to restate a point that I am not sure has rea
Post# of 5066
Posted On: 08/01/2013 8:54:52 AM
Just to restate a point that I am not sure has really been elaborated on is the possible ORPHAN status classification. IMHO, the IND approval is important for obvious reasons but getting an ORPHAN drug status classification is what I think will be the real catalyst in getting this stock moving north in a hurry. Plain and simple, we should all be hoping for the FDA to grant ORPHAN drug status for HemaXellerate I™.
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼